University of California Berkeley seal E. O. Lawrence Berkeley National Laboratory seal
The Carcinogenic Potency Project

p-Rosaniline.HCl (CAS 569-61-9)
SMILES, InChI and Structure are below.
Rats and Mice: Cancer Test Summary
Rat Target Sites Mouse Target Sites TD50 (mg/kg/day)
Male Female Male Female Rat Mouse
ezy liv ski sub thy ezy sub thy liv adr liv 39.4m 51.5m

Hamsters: Cancer Test Summary
Hamster Target Sites TD50
Male Female
no positive no positive no positive

Key to the Table Above

Positivity: For each chemical with a positive (carcinogenic) experiment in the Carcinogenic Potency Database (CPDB), results are included on carcinogenic potency (TD50) in each species and target sites in males and females. Positivity is determined by an author’s opinion in a published paper. If all experimental results in the CDPB are negative in a sex-species group, “no positive” appears. If the CPDB has no experiments in the sex-species group, “no test” appears. The summary presents the strongest evidence of carcinogenicity in each group. If there are both positive and negative experiments in a sex-species, the negative results are ignored in this Summary Table.
Target Site Codes:   adr = adrenal gland. ezy = ear/Zymbal’s gland. liv = liver. ski = skin. sub = subcutaneous tissue. thy = thyroid gland. Target sites are listed if any author of published experimental results concluded that tumors were induced in that organ by the test agent. If there is more than one positive experiment in a sex-species, target sites listed may be from more than one experiment, e.g. if liver and lung are both listed, then liver may have been a target in one experiment and lung in another.
TD50: Our standardized measure of carcinogenic potency, TD50, is the daily dose rate in mg/kg body weight/day to induce tumors in half of test animals that would have remained tumor-free at zero dose. Whenever there is more than one positive experiment in a species, the reported TD50 value is a Harmonic Mean calculated using the TD50 value from the most potent target site in each positive experiment.
Superscripts:   m = There is more than one positive experiment in the species, and TD50 values from each positive experiment are used in the calculation of the reported Harmonic mean of TD50.

The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.

For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD50) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.

Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD50 estimation for a standard lifespan. See Methods for other details.

TD50 provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD50 values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.

A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.

p-Rosaniline.HCl: All Experiments and Citations in CPDB

The definition of each code in the plot below will appear in a pop-up window when the field name in the header line is clicked, e.g., Strain, Site, Path. Each numbered line starts a new experiment and reports protocol information in black. Average daily dose-rates per kg body weight per day are in green. Remaining lines report experimental results in blue.

Abbreviations of fields in header line: # = the line number in the plot of all CPDB chemicals; Xpo = duration of dosing; Xpt = duration of experiment; Site = tissue; Path = tumor type; DR = dose-response; AuOp = author’s opinion about carcinogenicity; LoConf, UpConf = confidence limits (99%) on TD50; Inc = tumor incidence for each dose group.

See Guide to reading the plot for details on each field, using an example of one experiment.

See Help to improve readability, or to fit the plot onto the screen or a printed page.

Chemical (Synonym) CAS
# Species Sex Strain Route Xpo+Xpt PaperNum        0 Dose  1 Dose 2 Dose  3 Dose          Literature Reference or NCI/NTP:Site Path
Site Path Notes   TD50  DR Pval    AuOp LoConf UpConf   Cntrl   1 Inc  2 Inc   3 Inc                                                        Brkly Code

p-ROSANILINE.HCl (p-magenta, C.I. basic red 9.HCl) 569-61-9 5538 H f syg gav 84w84 1151 0 85.7mg Green;zkko,95,51-55;1979 liv tum e no dre P=1. n.s.s. 0/40 0/40 lun tum e no dre P=1. n.s.s. 0/40 0/40 tba mix e no dre P=1. - n.s.s. 5/40 4/40 5539 H m syg gav 84w84 1151 0 85.7mg liv tum e no dre P=1. n.s.s. 0/40 0/40 lun tum e no dre P=1. n.s.s. 0/40 0/40 tba mix e no dre P=1. - n.s.s. 3/40 1/40 5540 M f b6c eat 24m24 TR285 : 0 63.8mg liv MXA 20.3mg * P<.0005 13.5mg 32.3mg 5/50 35/50 41/50 liv:hpa,hpc. S MXB MXB 28.8mg * P<.0005 18.9mg 46.5mg 4/50 25/50 37/50 adr:phe,phm; liv:hpc. C liv hpc 32.3mg * P<.0005 c 20.9mg 52.5mg 3/50 19/50 37/50 liv hpa 35.9mg \ P<.0005 18.6mg 85.9mg 2/50 18/50 (4/50) S --- MXA 62.2mg * P<.0005 e 33.7mg 17/50 24/50 25/50 ---:mlh,mlm,mlp,mlu,mno. adr MXA 90.6mg * P<.0005 c 45.0mg 1/50 8/50 8/50 adr:phe,phm. --- mlp \ P<.002 e 51.6mg 0/50 5/50 (1/50) lun MXA * P<.002 1.35gm 0/50 2/50 5/50 lun:a/a,a/c. S hag MXA / P<.002 1.58gm 0/50 0/50 5/50 hag:adn,cyn. S lun a/a * P<.003 1.95gm 0/50 2/50 4/50 S --- mlh * P<.004 e 2.64gm 1/50 3/50 8/50 hag ade * P<.01 45.2gm 0/50 0/50 3/50 S hag MXA / P<.02 n.s.s. 1/50 0/50 5/50 hag:adn,can,cyn. S TBA MXB 23.4mg * P<.0005 14.7mg 44.0mg 31/50 50/50 49/50 liv MXB 20.3mg * P<.0005 13.5mg 32.3mg 5/50 35/50 41/50 liv:hpa,hpc,nnd. lun MXB * P<.002 1.35gm 0/50 2/50 5/50 lun:a/a,a/c. 5541 M m b6c eat 24m24 TR285 : 0 58.9mg liv hpc * P<.002 c 69.0mg 10/50 20/50 27/50 liv MXA * P<.04 50.1mg n.s.s. 29/50 37/50 41/50 liv:hpa,hpc. S --- mlm * P<.02 n.s.s. 0/50 3/50 4/50 S TBA MXB * P<.4 56.8mg n.s.s. 44/50 43/50 46/50 liv MXB * P<.04 50.1mg n.s.s. 29/50 37/50 41/50 liv:hpa,hpc,nnd. lun MXB no dre P=1. n.s.s. 11/50 7/50 8/50 lun:a/a,a/c. 5542 R f f34 eat 24m24 TR285 : 0 24.6mg 49.3mg mgl MXA 25.4mg * P<.0005 e 14.1mg 83.6mg 23/50 32/50 32/50 mgl:acn,adn,fba. mgl fba 27.9mg * P<.0005 e 15.0mg 22/50 31/50 29/50 MXB MXB 32.2mg * P<.0005 21.2mg 51.7mg 0/50 16/50 21/50 sub:fib; thy:fca,fcc; zym:can. C sub MXA 40.9mg * P<.0005 25.1mg 82.0mg 1/50 17/50 12/50 sub:fbs,fib,srn. S sub MXA 42.8mg * P<.0005 26.5mg 76.6mg 0/50 16/50 10/50 sub:fbs,fib. S sub fib 44.5mg * P<.0005 c 27.2mg 80.7mg 0/50 15/50 10/50 ute ess * P<.006 60.0mg 1.50gm 1/50 5/50 6/50 S thy MXA * P<.0005 c 68.8mg 0/50 2/50 6/50 thy:fca,fcc. zym can * P<.002 c 86.5mg 0/50 2/50 7/50 thy fca / P<.007 5.07gm 0/50 0/50 4/50 S mgl MXA * P<.03 e 63.2mg n.s.s. 2/50 4/50 6/50 mgl:acn,adn. liv MXA * P<.04 73.0mg n.s.s. 1/50 4/50 4/50 liv:hpc,nnd. S mgl acn * P<.06 e 79.3mg n.s.s. 2/50 2/50 5/50 TBA MXB 17.8mg * P<.0005 10.1mg 57.5mg 41/50 50/50 48/50 liv MXB * P<.04 73.0mg n.s.s. 1/50 4/50 4/50 liv:hpa,hpc,nnd. 5543 R m f34 eat 24m24 TR285 : 0 39.2mg 79.2mg tes ict 15.6mg / P<.0005 9.57mg 33.0mg 43/50 46/50 37/50 S MXB MXB 21.2mg / P<.0005 14.8mg 32.0mg 3/50 26/50 40/50 liv:hpc; ski:sea,sqc,tri; sub:fib; thy:fca,fcc; zym:can. C sub MXA 33.0mg / P<.0005 20.6mg 59.7mg 3/50 22/50 16/50 sub:fbs,fib. S sub MXA 33.4mg / P<.0005 20.8mg 62.6mg 6/50 24/50 19/50 sub:fbs,fib,srn. S sub fib 35.3mg / P<.0005 c 22.2mg 62.9mg 2/50 20/50 16/50 liv MXA 41.5mg / P<.0005 24.0mg 89.4mg 5/50 15/50 14/50 liv:hpc,nnd. S thy MXA 57.0mg / P<.0005 c 34.9mg 97.5mg 0/50 5/50 25/50 thy:fca,fcc. liv nnd 62.2mg * P<.0005 31.0mg 5/50 14/50 6/50 S thy fcc 73.9mg / P<.0005 c 42.1mg 0/50 5/50 18/50 ski MXA 93.8mg / P<.0005 47.9mg 2/50 2/50 14/50 ski:sqc,sqp. S zym can / P<.0005 c 61.6mg 1/50 1/50 13/50 ski sqc / P<.0005 c 61.7mg 0/50 1/50 10/50 liv hpc / P<.0005 c 65.7mg 0/50 2/50 8/50 pni MXA * P<.006 62.5mg 2.26gm 2/50 5/50 4/50 pni:isa,isc. S thy fca / P<.0005 c 78.3mg 0/50 0/50 9/50 ski tri / P<.0005 c 90.5mg 0/50 0/50 7/50 lun a/a * P<.006 98.7mg 2.79gm 0/50 3/50 3/50 S ski sea / P<.003 c 2.29gm 0/50 0/50 5/50 MXA MXA * P<.02 70.1mg 42.6gm 1/50 5/50 3/50 bod:men; mls:men; mul:men; tnv:men,msm. S pni isc * P<.02 85.2mg n.s.s. 0/50 3/50 1/50 S lun MXA * P<.02 90.9mg n.s.s. 1/50 3/50 4/50 lun:a/a,a/c. S ski bcc / P<.03 n.s.s. 1/50 0/50 4/50 S liv MXA / P<.02 n.s.s. 0/50 0/50 3/50 liv:bda,bdc. S TBA MXB 15.7mg / P<.0005 9.99mg 29.7mg 41/50 47/50 45/50 liv MXB 41.5mg / P<.0005 24.0mg 89.4mg 5/50 15/50 14/50 liv:hpa,hpc,nnd. 5544 R f sda gav 30m30 1524 0 48.6mg Ketkar;clet,16,203-206;1982 liv tum ev no dre P=1. n.s.s. 0/40 0/40 tba mix ev no dre P=1. - n.s.s. 23/40 11/40 5545 R m sda gav 29m29 1524 0 48.7mg liv tum ev no dre P=1. n.s.s. 0/40 0/40 tba mix ev no dre P=1. - n.s.s. 10/40 7/40

Mutagenicity in Salmonella: positive
SMILES Code for p-Rosaniline.HCl: C(C1=CC=C(C=C1)N)(C2=CC=C(C=C2)N)=C3C=CC(C=C3)=N.[HCl]
InChI Code for p-Rosaniline.HCl: InChI=1/C19H17N3.ClH/c20-16-7-1-13(2-8-16)19(14-3-9-17(21)10-4-14)15-5-11-18(22)12-6-15;/h1-12,20H,21-22H2;1H
Source for SMILES and InChI: USEPA Distributed Structure-Searchable Toxicity (DSSTox) Database
Chemical Structure for p-Rosaniline.HCl: Chemical Structure
Source for structure: National Library of Medicine ChemIDPlus

See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.

A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.

For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.

The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.

  1. A plot of the CPDB presents results of 1547 experiments on 6540 chemicals in an easily readable format that has been used in publications of the CPDB.
  2. A Screen version plot for use on a single computer screen, with the same data.
  3. Excel version of the same data.
  4. Tab-separated versions of the same data, which can be easily read into databases.

A Supplementary Dataset gives details on dosing and survival for each experiment.

Relatively precise estimates of the lower confidence limit on the TD10 (LTD10) are readily calculated from the TD50 and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD10 values, we provide them in an Excel spreadsheet.

PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.

Carcinogenic Potency Database Project (CPDB) Home Page
For more information about this Web Page, contact Specialized Information Services (
Last updated: October 3, 2007

PDF documents are best viewed with the free Adobe® Reader
Excel documents are best viewed with the free Excel® Viewer